7 active trials 4 recruiting 1 Phase 3 5 disease areas 10 changes in 30 days
6 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 5 with minor changes only.
Primary endpoint(s) modified
Also in this update: Results posted: Sep 25, 2026; Completion pushed from Mar 2026 to Dec 2026
Corcept TherapeuticsPhase 3 NCT05257408 Registry history of NCT05257408 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Corcept TherapeuticsPhase 1 NCT06947304 Registry history of NCT06947304 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Primary completion date changed from estimate of Sep 2026 to Feb 13, 2026
Corcept TherapeuticsPhase 2 NCT06108219 Registry history of NCT06108219 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Corcept TherapeuticsPhase 2 NCT05407324 Registry history of NCT05407324 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 44 → 48 locations
Corcept TherapeuticsPhase 2 NCT03604198 Registry history of NCT03604198 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 16 → 20 locations
Corcept TherapeuticsPhase 2 NCT07259317 Registry history of NCT07259317 on ClinicalTrials.gov (opens the registry)
Updated
| Phase 1 | 1 | |
| Phase 1/2 | 1 | |
| Phase 2 | 4 | |
| Phase 3 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT05257408 | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant… | Ovarian Neoplasm | Active, Not Recruiting | 2026-09-25 |
| Phase 2 | ||||
| NCT07259317 | Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic… | Adenocarcinoma | Recruiting | 2026-09-25 |
| NCT06906341 | Relacorilant in Combination With Different Treatment Regimens in Patients With… | Ovarian Cancer | Recruiting | 2026-07-16 |
| NCT03604198 | Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With… | Cushing Syndrome | Active, Not Recruiting | 2026-10-09 |
| NCT05407324 | Dazucorilant in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Active, Not Recruiting | 2026-09-24 |
| Phase 1/2 | ||||
| NCT07276373 | Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid… | Neoplasms | Recruiting | 2026-08-19 |
| Phase 1 | ||||
| NCT07553663 | Evaluating the Pharmacokinetics and Safety of Miricorilant | Nonalcoholic Steatohepatitis (NASH) | Recruiting | 2026-05-26 |
Ovarian Cancer (2) · ALS (1) · Endometrial Cancer (1) · NASH / MASH (1) · Pancreatic Cancer (1)